CURE Pharmaceutical announces two new members to its board of directors. Lauren Chung, Ph.D., has 20 years of healthcare investment management and advisory experience. Chung founded MINLEIGH LLC in 2012, identifying, evaluating and partnering with companies for investments and various strategic, operations and commercial planning, as well as providing growth capital. Anya Goldin has 28 years of experience across the law, private equity, venture capital, healthcare, and telecommunications industries. Goldin serves as a consultant, and is an attorney at Nolan Heimann law firm and teaches a course on International Business Negotiations at the University of Southern California’s Gould School of Law.
Also, VC Reporter mentions that CURE is developing a cannabinoid pharmaceutical product administered through a prescription-only oral thin film, which necessitates a very particular hemp product.
“We are a registered pharmaceutical company with the FDA . . . with Schedule 1 certification,” said Davidson. “We are the only company in the U.S. to have a Schedule 1 DEA license as a drug-delivery company.”
Read all the coverage:
BIZ BUZZ | Sept. 2019
GREEN RUSH | Ventura County issues permits for 4,000 acres of hemp
